PriceTargets.com logo

Amarin - AMRN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.00
  • Forecasted Upside: 73.01%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.58 As of 10/22/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for AMRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amarin Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMRN

Analyst Price Target is $1.00
▲ +73.01% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Amarin in the last 3 months. The average price target is $1.00, with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 73.01% upside from the last price of $0.58.

This chart shows the closing price for AMRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Amarin. This rating has held steady since June 2024, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
4/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/18/2024Cantor FitzgeraldReiterated RatingOverweight
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
11/20/2023JPMorgan Chase & Co.Reiterated RatingUnderweight
10/25/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$3.00 ➝ $1.00
7/20/2023The Goldman Sachs GroupLower TargetSell$1.50 ➝ $1.00
7/19/2023Northland SecuritiesLower Target$2.00 ➝ $1.25
1/6/2023Jefferies Financial GroupUpgradeHold ➝ Buy$1.30 ➝ $3.00
10/19/2022Leerink PartnersLower TargetMarket Perform$3.00 ➝ $2.00
5/24/2022The Goldman Sachs GroupLower TargetSell$1.75 ➝ $1.50
5/6/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
5/5/2022HC WainwrightDowngradeBuy ➝ Neutral$10.00 ➝ $3.00
5/5/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$10.00 ➝ $3.00
5/4/2022Northland SecuritiesDowngradeOutperform ➝ Market Perform
3/2/2022Cantor FitzgeraldReiterated RatingOverweight
2/16/2022Leerink PartnersLower TargetOutperform$11.00 ➝ $10.00
1/31/2022Leerink PartnersLower TargetOutperform$12.00 ➝ $11.00
9/26/2021Leerink PartnersReiterated RatingBuy$12.00
9/9/2021Leerink PartnersInitiated CoverageOutperform$12.00
8/9/2021HC WainwrightReiterated RatingBuy$10.00
6/11/2021Cantor FitzgeraldReiterated RatingBuy$10.00
5/18/2021The Goldman Sachs GroupReiterated RatingNeutral ➝ Sell$6.00 ➝ $5.00
5/12/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$6.00 ➝ $5.00
2/1/2021Leerink PartnersBoost TargetOutperform$12.00 ➝ $16.00
2/1/2021HC WainwrightReiterated RatingBuy
1/8/2021Piper SandlerReiterated RatingOverweight$19.00
12/23/2020The Goldman Sachs GroupLower Target$8.00 ➝ $6.00
12/7/2020Smith Barney CitigroupLower Target$12.00 ➝ $7.00
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutral
9/28/2020Leerink PartnersBoost TargetOutperform ➝ Outperform$9.00 ➝ $12.00
9/8/2020Cantor FitzgeraldLower Target$35.00 ➝ $15.00
9/3/2020Stifel NicolausLower TargetHold$8.00 ➝ $5.00
8/25/2020Piper SandlerInitiated CoverageOverweight$21.00
8/5/2020HC WainwrightReiterated RatingBuy
8/4/2020Stifel NicolausReiterated RatingHold$8.00
6/16/2020Stifel NicolausReiterated RatingHold
6/15/2020Cantor FitzgeraldReiterated RatingBuy$35.00
6/3/2020OppenheimerReiterated RatingHold
5/22/2020CowenReiterated RatingBuy$10.00
5/5/2020Northland SecuritiesInitiated CoverageOutperform$15.00
5/4/2020AegisBoost TargetBuy$9.00 ➝ $11.00
5/4/2020Leerink PartnersBoost TargetOutperform$7.00 ➝ $9.00
5/1/2020CitigroupBoost TargetBuy$6.00 ➝ $12.00
5/1/2020HC WainwrightReiterated RatingBuy
4/30/2020Stifel NicolausReiterated RatingHold$8.00
4/14/2020CowenBoost Target$8.00 ➝ $10.00
4/13/2020Stifel NicolausReiterated RatingHold
4/2/2020HC WainwrightReiterated RatingBuy$51.00
4/1/2020CitigroupLower TargetBuy$24.00 ➝ $6.00
3/31/2020Stifel NicolausLower TargetHold$24.00 ➝ $8.00
3/31/2020OppenheimerUpgradeUnderperform ➝ Market Perform
3/31/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$27.00 ➝ $4.00
3/31/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$30.00 ➝ $4.00
3/13/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$11.50 ➝ $28.00
3/2/2020CowenInitiated CoverageOutperform$23.00
2/27/2020Stifel NicolausReiterated RatingHold$24.00
2/26/2020OppenheimerLower TargetUnderperform$13.00 ➝ $12.00
2/26/2020HC WainwrightReiterated RatingBuy ➝ Positive$51.00
2/18/2020CitigroupUpgradeNeutral ➝ Buy$27.00 ➝ $24.00
1/22/2020OppenheimerReiterated RatingSell$8.00 ➝ $13.00
1/14/2020Jefferies Financial GroupReiterated RatingBuy$30.00
1/9/2020HC WainwrightReiterated RatingBuy$51.00
1/7/2020Stifel NicolausReiterated RatingHold
1/6/2020JPMorgan Chase & Co.Initiated CoverageNeutral$22.00
1/2/2020Cantor FitzgeraldReiterated RatingBuy$35.00
12/20/2019Cantor FitzgeraldReiterated RatingBuy$35.00
12/16/2019OppenheimerBoost TargetUnderperform$7.00 ➝ $8.00
12/16/2019Stifel NicolausDowngradeBuy ➝ Hold$26.00 ➝ $28.00
12/13/2019Leerink PartnersReiterated RatingBuy$29.00
12/3/2019Roth CapitalReiterated RatingBuy$31.00
12/2/2019Leerink PartnersReiterated RatingBuy$29.00
12/2/2019Cantor FitzgeraldReiterated RatingBuy$35.00
11/29/2019Jefferies Financial GroupReiterated RatingBuy$30.00
11/27/2019CitigroupDowngradeBuy ➝ Neutral
11/19/2019OppenheimerInitiated CoverageUnderperform$7.00 ➝ $7.00
11/18/2019CitigroupDowngradeBuy ➝ Neutral$23.00 ➝ $27.00
11/15/2019Leerink PartnersBoost Target$28.00 ➝ $29.00
11/13/2019Cantor FitzgeraldReiterated RatingBuy$35.00
11/12/2019Stifel NicolausReiterated RatingBuy
11/6/2019HC WainwrightReiterated RatingBuy
10/31/2019AegisInitiated CoverageBuy$23.00
(Data available from 10/23/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/27/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
5/26/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/23/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Amarin logo
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $0.58
Low: $0.57
High: $0.59

50 Day Range

MA: $0.60
Low: $0.57
High: $0.67

52 Week Range

Now: $0.58
Low: $0.57
High: $1.37

Volume

917,426 shs

Average Volume

1,558,904 shs

Market Capitalization

$237.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Amarin?

The following Wall Street sell-side analysts have issued reports on Amarin in the last twelve months: Cantor Fitzgerald, Jefferies Financial Group Inc., JPMorgan Chase & Co., and StockNews.com.
View the latest analyst ratings for AMRN.

What is the current price target for Amarin?

1 Wall Street analysts have set twelve-month price targets for Amarin in the last year. Their average twelve-month price target is $1.00, suggesting a possible upside of 73.0%. Jefferies Financial Group Inc. has the highest price target set, predicting AMRN will reach $1.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $1.00 for Amarin in the next year.
View the latest price targets for AMRN.

What is the current consensus analyst rating for Amarin?

Amarin currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMRN, but not buy more shares or sell existing shares.
View the latest ratings for AMRN.

What other companies compete with Amarin?

Other companies that are similar to Amarin include Heron Therapeutics, Generation Bio, Zymeworks, Cullinan Therapeutics and Rapport Therapeutics. Learn More about companies similar to Amarin.

How do I contact Amarin's investor relations team?

Amarin's physical mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company's listed phone number is (531) 669-9020 and its investor relations email address is [email protected]. The official website for Amarin is www.amarincorp.com. Learn More about contacing Amarin investor relations.